European Penny Stocks: 3 Promising Picks Under €70M Market Cap

Mon, Sep 8, 2025, 2:05 AM 4 min read

Amid recent concerns about global growth and a stronger euro, the European markets have shown mixed performance, with the pan-European STOXX Europe 600 Index ending slightly lower. In such fluctuating market conditions, investors often look for opportunities in smaller or newer companies that might offer potential for growth. While the term “penny stocks” may seem outdated, these investments can still represent valuable prospects when they exhibit strong financials and stability.

Click here to see the full list of 329 stocks from our European Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Aiforia Technologies Oyj, along with its subsidiary Aiforia Inc., offers AI-based image analysis software for clinical, preclinical, and academic laboratories globally, serving pathologists and researchers, with a market cap of €92.29 million.

Operations: The company’s revenue is primarily generated from its healthcare software segment, amounting to €2.88 million.

Market Cap: €92.29M

Aiforia Technologies Oyj, with a market cap of €92.29 million, is making strides in the AI-driven pathology sector despite being unprofitable and generating modest revenue of €2.88 million primarily from healthcare software. The company’s strategic alliance with Dedalus Group aims to integrate AI into pathology workflows, addressing global demands for more efficient diagnostics amid rising cancer cases and pathologist shortages. Aiforia’s recent expansion into France supports its growth ambitions in a country heavily investing in AI technologies. Financially, it has reduced its debt significantly over five years but faces challenges with less than a year of cash runway remaining.

• Get an in-depth perspective on Aiforia Technologies Oyj’s performance by reading our balance sheet health report here.

• Gain insights into Aiforia Technologies Oyj’s outlook and expected performance with our report on the company’s earnings estimates.

Simply Wall St Financial Health Rating: ★★★★★☆